Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVA85A/AERAS-485 for TB prevention in BCG-vaccinated infants
NCT00953927Phase 2Completed
- Sponsor
- Aeras Global Vaccine Foundation
- Start
- Jul 2009
- Primary completion
- Oct 2012
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MVA85A in Tuberculosis (TB), sponsored by Aeras Global Vaccine Foundation. Primary endpoint: Safety Profile of MVA85A/AERAS-485 at 36 months. Started Jul 2009; status: completed.
02
Drugs
MVA85A
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT00953927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00953927.